Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Delivers Shareholders Stellar 23% CAGR Over 5 Years, Surging 4.7% in the Last Week Alone
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Jefferies Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $40
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $39
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
Roth MKM Says Small-Cap Value Reaches Key Technical Support, Lists 14 "Bullish" Stocks
New Strong Buy Stocks for August 1st
Express News | Kiniksa Pharmaceuticals Ltd : JP Morgan Raises Target Price to $38 From $30
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $578,966, According to a Recent SEC Filing
Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$3.49 Million in Common Stock
Kiniksa Pharmaceuticals International | 10-Q: Q2 2024 Earnings Report
Kiniksa Pharmaceuticals International And Two More Firms Possibly Priced Below Market Value Estimates
There's No Escaping Kiniksa Pharmaceuticals International, Plc's (NASDAQ:KNSA) Muted Revenues Despite A 41% Share Price Rise
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30
Express News | Kiniksa Pharmaceuticals Ltd. : Wells Fargo Raises Target Price to $35 From $34
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35
Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q2 2024 Earnings Conference
Form 144 | Kiniksa Pharmaceuticals International(KNSA.US) Officer Proposes to Sell 3.49 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 23, $Kiniksa Pharmaceuticals International(KNSA.US)$ Officer Patel Sanj K intends to sell 136.12K shares of its common stock on Jul 23, with a total market value of
Kiniksa Pharmaceuticals International, Plc (KNSA) Q2 2024 Earnings Call Transcript
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34